November 11 | 2020
2cureX presents commercial roadmap 2021 – 2023
Read more
October 1 | 2020
Den sista patienten är registrerad med framgång i världens första interventionsstudie med 3D-mikrotumörer som vägledning för val av cancerbehandling.
Read more
October 1 | 2020
Last patient successfully enrolled in the world’s first interventional trial with 3D microtumors as guide for choice of cancer treatment.
Read more
September 14 | 2020
2cureX launches world’s first CE-marked microtumor test service
Read more
September 14 | 2020
2cureX launches world’s first CE-marked microtumor test service
Read more
July 1 | 2020
2cureX Newsletter July’20
Read more
June 25 | 2020
2cureX receives third payment from the EU’ Horizon 2020 SME- Instrument Program
Read more
June 25 | 2020
2cureX receives third payment from the EU’ Horizon 2020 SME- Instrument Program
Read more
June 16 | 2020
2cureX AB establishes collaboration with Scandion Oncology A/S and Erasmus Medical Centre, Rotterdam, in drug-resistant breast cancer patients
Read more
June 16 | 2020
2cureX AB establishes collaboration with Scandion Oncology A/S and Erasmus Medical Centre, Rotterdam, in drug-resistant breast cancer patients
Read more
June 9 | 2020
Byte av Certified Adviser till Redeye AB
Read more
June 9 | 2020
Change of Certified Adviser to Redeye AB
Read more
May 29 | 2020
2cureX moves forward with the commercialization of IndiTreat by signing a new distributor agreement in Portugal
Read more
May 29 | 2020
2cureX moves forward with the commercialization of IndiTreat by signing a new distributor agreement in Portugal
Read more
April 29 | 2020
2cureX German subsidiary receives a grant contribution to support the activities towards automation of the IndiTreat® test
Read more
April 29 | 2020
2cureX German subsidiary receives a grant contribution to support the activities towards automation of the IndiTreat® test
Read more